Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2015

View Archived Issues

Genmab buys anti-DR5 antibodies and IP from iDD Biotech

Selexipag shows efficacy for the treatment of PAH

Stevia and BioViva collaborate on genetic therapies for diabetes and obesity

Vect-Horus discloses neurotensin analogue for therapeutic hypothermia induction

Janssen patents mGluR2 positive allosteric modulators

Bristol-Myers Squibb describes RORgamma modulators

Biogen: new identity for Biogen Idec

Artery Therapeutics presents data on ABCA1 agonist peptide CS-6253

EAU Madrid: Long-term results from the everolimus EXIST-2 trial

High clinical efficacy of ranpirnase demonstrated against HPV infection

Masitinib receives FDA orphan drug designation for amyotrophic lateral sclerosis

Gilead Sciences begins phase I study of GS-5829

Celdara Medical begins phase I trial of chimeric-antigen receptor T cells

Stempeucel receives EMA advanced therapy medicinal product classification

Prozymex patents DPP-I inhibitors

Hayashikane Sangyo develops blood-vessel improving agents

Scancell's SCIB-2 DNA vaccine synergizes with immune checkpoint inhibitors against tumor cells

Orphan Technologies enzyme replacement therapy receives U.S. orphan designation for homocystinuria

University of Copenhagen's placental malaria vaccine ready for phase I studies

World Tuberculosis Day: a reminder about the ongoing epidemic

Medigene initiates first company-sponsored study of DC vaccine for AML

Takeda licenses rights to ImmunoGen's antibody-drug conjugate technology

Cerulean's phase Ib/II trial of CRLX-101 and bevacizumab in RCC meets primary endpoint

Vertex reports on phase II trial of VX-661 and ivacaftor in F508del-homozygous CF

First proof-of-concept for 64Cu-DOTA-AE-105 in bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...